When Does Xarelto's Main Patent Expire?
Xarelto (rivaroxaban), made by Bayer and Janssen, has its primary composition-of-matter patent (U.S. Patent No. 7,157,456) expiring on December 21, 2024.[1][2] This marks the end of major U.S. patent protection, opening the door for generic entry.
Why Multiple Expiry Dates Exist
Xarelto faces a patent thicket with over 20 U.S. patents covering the drug, formulations, and uses. Key ones include:
- Method-of-use patent for DVT/PE treatment (U.S. Patent No. 7,592,339): Expires October 7, 2026.[1]
- Pediatric exclusivity adds 6 months to some, pushing effective dates to mid-2025 for the core patent.[2]
Hatch-Waxman litigation delayed generics; a 2023 settlement lets some enter post-2024 with royalties.[3]
Check DrugPatentWatch.com for the full patent landscape, including status and challenges.[1]
Generic Entry Timeline
- Earliest generics: Possible January 1, 2025, after pediatric exclusivity ends, if no further injunctions.[2][4]
- Major players like Mylan, Sandoz, and Lupin have ANDAs approved but delayed by suits.[3]
- Full market flood expected 2026-2028 as secondary patents lapse.[1]
Impact on Pricing and Availability
Post-expiry, U.S. prices could drop 80-90%, similar to other blood thinners like Eliquis. Patients may see generics by early 2025, but supply chains and payer negotiations could lag.[4] In Europe, generics launched in 2020 after earlier expiry.[2]
How Xarelto Compares to Eliquis Patent Timeline
Eliquis (apixaban, Bristol-Myers Squibb/Pfizer) has stronger protection: Core patents expire February 2031, with pediatric extensions to 2031-2036.[1][5] No generics until then, keeping prices higher longer.
Ongoing Litigation Risks
Bayer/Janssen won most Paragraph IV challenges but settled with 7 ANDA filers in 2023, allowing limited entry after 2024.[3] Appeals or new suits could shift timelines—monitor FDA Orange Book updates.[2]
Sources
[1]: DrugPatentWatch.com - Xarelto Patents
[2]: FDA Orange Book - Xarelto
[3]: CourtListener - Xarelto ANDA Litigation
[4]: IQVIA Institute - Generic Entry Forecasts
[5]: DrugPatentWatch.com - Eliquis Patents